Crossmark

High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia

Published Online: 2024-07-04

Published Print: 2024-09

Authors

Oya, Shuki

Ozawa, Hidetoshi

Morishige, Satoshi

Maehiro, Yoshimi

Umeda, Masahiro

Takaki, Yusuke

Fukuyama, Toshinobu

Yamasaki, Yoshitaka

Nakamura, Takayuki

Yamaguchi, Maki

Aoyama, Kazutoshi

Mouri, Fumihiko

Nagafuji, Koji https://orcid.org/0000-0003-4795-121X
License Information

Text and Data Mining valid from 2024-07-04

Version of Record valid from 2024-07-04
More Information

Article History

Received: 4 March 2024

Revised: 26 June 2024

Accepted: 26 June 2024

First Online: 4 July 2024

Declarations

:

: The authors declare no conflict of interest.

Document is current